Suppr超能文献

通过结构启发式虚拟筛选研究发现新型微粒体前列腺素E合酶1(mPGES-1)抑制剂。

Discovery of novel microsomal prostaglandin E synthase 1 (mPGES-1) inhibitors by a structurally inspired virtual screening study.

作者信息

Olğaç Abdurrahman, Jordan Paul M, Kretzer Christian, Werz Oliver, Banoglu Erden

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06560, Ankara, Turkey; Department of Drug Discovery, Evias Pharmaceutical R&D Ltd., Gazi Teknopark, 06830, Ankara, Turkey.

Department of Pharmaceutical/Medicinal Chemistry, Friedrich Schiller University Jena, 07743, Jena, Germany.

出版信息

J Mol Graph Model. 2025 May;136:108962. doi: 10.1016/j.jmgm.2025.108962. Epub 2025 Jan 30.

Abstract

Prostaglandin (PG) E is a pro-inflammatory lipid mediator derived from the metabolism of arachidonic acid (AA) by cyclooxygenases (COX) and PGE synthases. Nonsteroidal anti-inflammatory drugs (NSAIDs), commonly used in the treatment of inflammation, nonselectively inhibit COX activity and decrease PGE production. However, these drugs cause gastrointestinal bleeding and several cardiovascular complications. Therefore, inhibiting microsomal PGE Synthase-1 (mPGES-1) to block PGE production downstream of COX is expected to yield safer and more effective treatments for inflammation, cancer, and cardiovascular diseases. At present, there are no mPGES-1 inhibitors available on the market, but ongoing research continuously evaluates new compounds in both preclinical and clinical stages. Here, we conducted a high throughput virtual screening campaign to discover novel mPGES-1 inhibitor scaffolds. This campaign utilized physicochemical filtering alongside both structure-aware ligand-based approaches (shape screening templates and pharmacophore models, which were generated based on the 3D binding modes of the co-crystallized mPGES-1 inhibitors) and structure-based strategies (refinement with docking and molecular dynamics). Thirty-four compounds were selected and biologically tested for mPGES-1 inhibition in a cell-free assay using microsomes from interleukin-1β-stimulated A549 cells as the source of mPGES-1. The most potent compound inhibited the remaining enzyme activity with an IC value of 6.46 μM in a cell-free assay for PGE production. We also compared the binding patterns of the most active compounds identified in this study with those of co-crystallized inhibitors using molecular dynamics simulations. This comparison underscored the crucial role of ionic interactions, π-π interactions, hydrogen bonds, and water bridges involving specific amino acids. Our results highlight the importance of these interaction networks within the binding cavity in various binding scenarios. Ultimately, the insights gained from this study could assist in designing and developing new mPGES-1 inhibitors.

摘要

前列腺素(PG)E是一种促炎脂质介质,由花生四烯酸(AA)经环氧化酶(COX)和PGE合酶代谢产生。常用于治疗炎症的非甾体抗炎药(NSAIDs)非选择性抑制COX活性并减少PGE生成。然而,这些药物会导致胃肠道出血和多种心血管并发症。因此,抑制微粒体PGE合酶-1(mPGES-1)以阻断COX下游的PGE生成有望为炎症、癌症和心血管疾病带来更安全、更有效的治疗方法。目前市场上没有mPGES-1抑制剂,但正在进行的研究在临床前和临床阶段不断评估新化合物。在此,我们开展了一项高通量虚拟筛选活动,以发现新型mPGES-1抑制剂骨架。该活动利用物理化学筛选,结合基于结构的配体方法(形状筛选模板和药效团模型,基于共结晶mPGES-1抑制剂的3D结合模式生成)和基于结构的策略(通过对接和分子动力学进行优化)。选择了34种化合物,并使用来自白细胞介素-1β刺激的A549细胞的微粒体作为mPGES-1来源,在无细胞试验中对其进行mPGES-1抑制的生物学测试。在PGE生成的无细胞试验中,最有效的化合物抑制剩余酶活性的IC值为6.46μM。我们还使用分子动力学模拟比较了本研究中鉴定的最具活性的化合物与共结晶抑制剂的结合模式。这种比较强调了涉及特定氨基酸的离子相互作用、π-π相互作用、氢键和水桥的关键作用。我们的结果突出了结合腔内这些相互作用网络在各种结合情况下的重要性。最终,本研究获得的见解有助于设计和开发新的mPGES-1抑制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验